NeuroOne,Inc. 14605Woodhaven Road Minnetonka,MN 55345 January 9, 2017

EX-10.19 21 v468812_ex10-19.htm EXHIBIT 10.19

 

Exhibit 10.19

 

NeuroOne, Inc.

14605 Woodhaven Road

Minnetonka, MN 55345

 

January 9, 2017

 

Thomas Bachinski 

19059 Orchard Trail

Lakeville, MN 55044

 

Dear Thomas: 

 

We are pleased to offer you employment with NeuroOne, Inc., a Delaware corporation (the “Company”). The terms of your offer are as follows:

 

Your initial position with us will be as Chief Development Officer. Beginning January 1, 2017, your annualized salary will be $231,000, paid in equal monthly installments in accordance with our normal payroll procedures, and you will be eligible to receive an annual bonus of up to 25% of your annualized salary, to be determined by the Company’s Board of Directors (the “Board”) in its sole discretion. In addition, you shall receive, in such form and at such time as determined by the Board, a grant of equity interests in the Company equal to 4% of the Company on a fully diluted basis as of the date hereof, which shall vest in connection with the achievement of milestones as set forth in the attached Exhibit A; provided, however, that achievement of such milestones shall be determined in the sole discretion of the Board. During your employment, you will be allowed to participate in the benefit programs and arrangements that we make available to our employees, including four (4) weeks paid vacation and sick leave, contributory and non-contributory welfare and benefit plans, disability plans, and medical, death benefit and life insurance plans for which you are eligible under the terms of those plans.

 

Your employment will be subject to the terms of the Company’s employee handbook (as amended from time to tome), which will supplement this letter agreement and is expressly incorporated by reference into this letter agreement. In addition, your job duties, title, responsibility and reporting level, compensation and benefits, as well as personnel policies and procedures, are subject to change.

 

Your employment is effective January 23, 2017. By signing this letter agreement, you acknowledge and agree that your employment with the Company is “at will,” meaning that either you or the Company are entitled to terminate your employment at any time for any reason, with or without cause. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express writing signed by you and the Board of Directors of the Company.

 

You are required, as a condition to your employment with the Company, to sign the Company’s standard Employee Proprietary Information, Inventions Assignment and Non-Competition Agreement in the form attached hereto as Exhibit B.

 

This letter agreement and its attachments contain all of the terms of your employment with the Company and supersedes any prior understandings or agreements, whether oral or written, between you and the Company.

 

This letter agreement may not be amended or modified except by an express written agreement signed by you and a duly authorized member of the Company’s Board of Directors. The terms of this letter agreement shall be governed by and construed in accordance with the internal laws of the State of Minnesota, without regard to its principles of conflicts of laws. By signing this letter agreement you irrevocably submit to the exclusive jurisdiction of the state and federal courts of the State of Minnesota for the purpose of any suit, action, proceeding or judgment relating to or arising out of this letter agreement and the transactions contemplated hereby.  BY SIGNING THIS LETTER AGREEMENT YOU ALSO WAIVE ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS LETTER AGREEMENT AND REPRESENT THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

 1 

 

 

We hope that you find the foregoing terms acceptable. You may indicate your agreement with these terms and accept this offer by signing and dating duplicate original copies of this letter agreement and the enclosed Employee Proprietary Information, Inventions Assignment and Non-Competition Agreement and returning them to me. As required by law, your employment with the Company is also contingent upon you providing legal proof of your identity and authorization to work in the United States.

 

Sincerely,

 

Dave A. Rosa, CEO

 

ACKNOWLEDGEMENT AND ACCEPTANCE

 

I have read and accept this employment offer. By signing this letter agreement, I represent and warrant to the Company that I am under no contractual commitments inconsistent with my obligations to the Company. Further, in consideration of my employment, I agree that, unless a shorter period of limitations applies, any claim, suit, action or other proceeding arising out of my employment or the termination of my employment, including but not limited to claims arising under state or federal civil rights statutes, must be brought or asserted by me within six (6) months of the event giving rise to the claim or be forever barred. I expressly waive any longer statute or other period of limitations to the contrary.

 

/s/ Thomas Bachinski   Dated: January 9, 2017
Thomas Bachinski    

 

 2 

 

 

EXHIBIT A

 

Vesting Milestones

 

1.Work with Evergreen Inc. on  the design history files for the cortical electrode and all other work performed by Evergreen that spans development to commercialization. This will support the regulatory 510k submission and generate a product development timeline that will synchronize / coordinate key functions in the organization. This needs to be done asap.  - Q1, 2017

 

2.Lead / Co-lead the development coordination of the depth electrode product specification and conversion into a design specification. – Q2-Q3 2017

 

3.Develop synchronization chart for business and engineering milestones for a 2017 timeline. Part of our 2017 planning session. - Q1, 2017

 

4.Develop Clinical Connector Strategy (Flex to wired interface). This will include product specification, interface to signal recording specification and preliminary design specification for sourcing or development by Q2 2017 or sooner.

 

 Exhibit A - 1